AAPL   322.16 (+1.03%)
MSFT   185.22 (+0.93%)
FB   240.18 (+2.24%)
GOOGL   1,440.68 (+1.94%)
AMZN   2,454.38 (+0.64%)
NVDA   362.80 (+0.38%)
CGC   20.64 (+5.47%)
BABA   205.95 (+3.13%)
TSLA   827.26 (+1.27%)
AMD   55.88 (+0.81%)
T   30.71 (+2.78%)
ACB   15.58 (-2.68%)
F   5.92 (+4.60%)
GILD   72.97 (-0.50%)
NFLX   423.47 (-1.36%)
BAC   23.87 (+5.34%)
BA   144.21 (+4.86%)
AAPL   322.16 (+1.03%)
MSFT   185.22 (+0.93%)
FB   240.18 (+2.24%)
GOOGL   1,440.68 (+1.94%)
AMZN   2,454.38 (+0.64%)
NVDA   362.80 (+0.38%)
CGC   20.64 (+5.47%)
BABA   205.95 (+3.13%)
TSLA   827.26 (+1.27%)
AMD   55.88 (+0.81%)
T   30.71 (+2.78%)
ACB   15.58 (-2.68%)
F   5.92 (+4.60%)
GILD   72.97 (-0.50%)
NFLX   423.47 (-1.36%)
BAC   23.87 (+5.34%)
BA   144.21 (+4.86%)
AAPL   322.16 (+1.03%)
MSFT   185.22 (+0.93%)
FB   240.18 (+2.24%)
GOOGL   1,440.68 (+1.94%)
AMZN   2,454.38 (+0.64%)
NVDA   362.80 (+0.38%)
CGC   20.64 (+5.47%)
BABA   205.95 (+3.13%)
TSLA   827.26 (+1.27%)
AMD   55.88 (+0.81%)
T   30.71 (+2.78%)
ACB   15.58 (-2.68%)
F   5.92 (+4.60%)
GILD   72.97 (-0.50%)
NFLX   423.47 (-1.36%)
BAC   23.87 (+5.34%)
BA   144.21 (+4.86%)
AAPL   322.16 (+1.03%)
MSFT   185.22 (+0.93%)
FB   240.18 (+2.24%)
GOOGL   1,440.68 (+1.94%)
AMZN   2,454.38 (+0.64%)
NVDA   362.80 (+0.38%)
CGC   20.64 (+5.47%)
BABA   205.95 (+3.13%)
TSLA   827.26 (+1.27%)
AMD   55.88 (+0.81%)
T   30.71 (+2.78%)
ACB   15.58 (-2.68%)
F   5.92 (+4.60%)
GILD   72.97 (-0.50%)
NFLX   423.47 (-1.36%)
BAC   23.87 (+5.34%)
BA   144.21 (+4.86%)
Log in

NASDAQ:BBIOBridgeBio Pharma Stock Price, Forecast & News

$35.00
+0.27 (+0.78 %)
(As of 05/26/2020 08:57 AM ET)
Add
Compare
Today's Range
$34.33
Now: $35.00
$35.29
50-Day Range
$22.22
MA: $30.19
$35.00
52-Week Range
$14.23
Now: $35.00
$48.36
Volume222,800 shs
Average Volume477,938 shs
Market Capitalization$4.25 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company was founded in 2015 and is headquartered in Palo Alto, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BBIO
CUSIPN/A
CIKN/A
Phone650-391-9740

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.56 million
Book Value$3.83 per share

Profitability

Miscellaneous

Employees152
Market Cap$4.25 billion
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive BBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.

BridgeBio Pharma (NASDAQ:BBIO) Frequently Asked Questions

How has BridgeBio Pharma's stock been impacted by COVID-19 (Coronavirus)?

BridgeBio Pharma's stock was trading at $23.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BBIO stock has increased by 46.6% and is now trading at $35.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BridgeBio Pharma?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last year. There are currently 1 sell rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BridgeBio Pharma.

When is BridgeBio Pharma's next earnings date?

BridgeBio Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for BridgeBio Pharma.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma (NASDAQ:BBIO) posted its earnings results on Wednesday, May, 13th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.69) by $0.09. View BridgeBio Pharma's earnings history.

What price target have analysts set for BBIO?

11 brokers have issued 1-year target prices for BridgeBio Pharma's stock. Their forecasts range from $38.00 to $51.00. On average, they anticipate BridgeBio Pharma's stock price to reach $45.10 in the next twelve months. This suggests a possible upside of 28.9% from the stock's current price. View analysts' price targets for BridgeBio Pharma.

Has BridgeBio Pharma been receiving favorable news coverage?

News headlines about BBIO stock have been trending negative on Tuesday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BridgeBio Pharma earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutBridgeBio Pharma.

Are investors shorting BridgeBio Pharma?

BridgeBio Pharma saw a drop in short interest in April. As of April 15th, there was short interest totaling 8,630,000 shares, a drop of 6.3% from the March 31st total of 9,210,000 shares. Based on an average daily trading volume, of 967,600 shares, the days-to-cover ratio is presently 8.9 days. Currently, 12.1% of the company's shares are short sold. View BridgeBio Pharma's Current Options Chain.

Who are some of BridgeBio Pharma's key competitors?

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Gilead Sciences (GILD), Fate Therapeutics (FATE), Myovant Sciences (MYOV), Opko Health (OPK), Pfizer (PFE), Advanced Micro Devices (AMD), Carnival (CCL), Crispr Therapeutics (CRSP), Las Vegas Sands (LVS) and Occidental Petroleum (OXY).

Who are BridgeBio Pharma's key executives?

BridgeBio Pharma's management team includes the following people:
  • Dr. Neil Kumar, Co-Founder, CEO & Director (Age 40)
  • Dr. Brian C. Stephenson, Chief Financial Officer (Age 38)
  • Dr. Uma Sinha, Chief Scientific Officer (Age 62)
  • Dr. Cameron Turtle, Sr. VP of Portfolio Management & Corp. Devel. (Age 29)
  • Dr. Charles J. Homcy, Chairman of Pharmaceuticals & Director (Age 71)

When did BridgeBio Pharma IPO?

(BBIO) raised $225 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

What is BridgeBio Pharma's stock symbol?

BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO."

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include American International Group Inc. (4.88%), BlackRock Inc. (4.30%), Aisling Capital Management LP (3.29%), Cormorant Asset Management LP (2.43%), Janus Henderson Group PLC (1.47%) and State Street Corp (1.41%). Company insiders that own BridgeBio Pharma stock include Brian C Stephenson, Cameron Turtle, Charles J Homcy, Frank Mccormick, Genetic Disorder LP Kkr, Global Investors Lp Viking, Michael Thomas Henderson and Neil Kumar. View institutional ownership trends for BridgeBio Pharma.

Which institutional investors are selling BridgeBio Pharma stock?

BBIO stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, American International Group Inc., Nuveen Asset Management LLC, Morgan Stanley, TimesSquare Capital Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., and Parametric Portfolio Associates LLC. Company insiders that have sold BridgeBio Pharma company stock in the last year include Brian C Stephenson, Cameron Turtle, Charles J Homcy, Frank Mccormick, Michael Thomas Henderson, and Neil Kumar. View insider buying and selling activity for BridgeBio Pharma.

Which institutional investors are buying BridgeBio Pharma stock?

BBIO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Cormorant Asset Management LP, Geode Capital Management LLC, JPMorgan Chase & Co., HighTower Advisors LLC, Aisling Capital Management LP, and Bank of New York Mellon Corp. Company insiders that have bought BridgeBio Pharma stock in the last two years include Brian C Stephenson, Genetic Disorder LP Kkr, Global Investors Lp Viking, and Michael Thomas Henderson. View insider buying and selling activity for BridgeBio Pharma.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BridgeBio Pharma's stock price today?

One share of BBIO stock can currently be purchased for approximately $35.00.

How big of a company is BridgeBio Pharma?

BridgeBio Pharma has a market capitalization of $4.25 billion and generates $40.56 million in revenue each year. The company earns $-260,590,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. BridgeBio Pharma employs 152 workers across the globe.

What is BridgeBio Pharma's official website?

The official website for BridgeBio Pharma is bridgebio.com.

How can I contact BridgeBio Pharma?

BridgeBio Pharma's mailing address is 421 Kipling Street, Palo Alto CA, 94301. The company can be reached via phone at 650-391-9740.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.